Meta-prediction of coronary artery disease risk
- PMID: 40240837
- DOI: 10.1038/s41591-025-03648-0
Meta-prediction of coronary artery disease risk
Erratum in
-
Author Correction: Meta-prediction of coronary artery disease risk.Nat Med. 2025 Sep;31(9):3204. doi: 10.1038/s41591-025-03925-y. Nat Med. 2025. PMID: 40830664 No abstract available.
Abstract
Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide, and accurately predicting individual risk is critical for prevention. Here we aimed to integrate unmodifiable risk factors, such as age and genetics, with modifiable risk factors, such as clinical and biometric measurements, into a meta-prediction framework that produces actionable and personalized risk estimates. In the initial development of the model, ~2,000 predictive features were considered, including demographic data, lifestyle factors, physical measurements, laboratory tests, medication usage, diagnoses and genetics. To power our meta-prediction approach, we stratified the UK Biobank into two primary cohorts: first, a prevalent CAD cohort used to train predictive models for cross-sectional prediction at baseline and prospective estimation of contributing risk factor levels and diagnoses (baseline models) and, second, an incident CAD cohort using, in part, these baseline models as meta-features to train a final CAD incident risk prediction model. The resultant 10-year incident CAD risk model, composed of 15 derived meta-features with multiple embedded polygenic risk scores, achieves an area under the curve of 0.84. In an independent test cohort from the All of Us research program, this model achieved an area under the curve of 0.81 for predicting 10-year incident CAD risk, outperforming standard clinical scores and previously developed integrative models. Moreover, this framework enables the generation of individualized risk reduction profiles by quantifying the potential impact of standard clinical interventions. Notably, genetic risk influences the extent to which these interventions reduce overall CAD risk, allowing for tailored prevention strategies.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: A.T. declares that he is a cofounder and equity shareholder of GeneXwell Inc. A.T. is an advisor to InsideTracker. The other authors declare no competing interests.
Update of
-
Meta-Prediction of Coronary Artery Disease Risk.Res Sq [Preprint]. 2023 Dec 20:rs.3.rs-3694374. doi: 10.21203/rs.3.rs-3694374/v1. Res Sq. 2023. Update in: Nat Med. 2025 Jul;31(7):2277-2288. doi: 10.1038/s41591-025-03648-0. PMID: 38196609 Free PMC article. Updated. Preprint.
References
-
- Damask, A. et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation https://doi.org/10.1161/CIRCULATIONAHA.119.044434 (2020).
-
- Marston, N. A. et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score. Circulation https://doi.org/10.1161/CIRCULATIONAHA.119.043805 (2020).
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous